Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,134.93 -4.33 -0.14%
FTSE 100 6,593.07 8.90 0.14%
DAX 9,321.00 3.18 0.03%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community



   Clinical Trials, New Orders, Improved Services, and Approvals - Research
 Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine
                   Biosciences, and Alnylam Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 3, 2013

NEW YORK, September 3, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting CareFusion
Corporation (NYSE: CFN), St. Jude Medical, Inc. (NYSE: STJ), Community Health
Systems Inc. (NYSE: CYH), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), and
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

CareFusion Corporation Research Report  

On August 27, 2013, CareFusion Corporation (CareFusion) announced that the
Company has simplified the ordering process for its line of surgical products
through an interactive e-catalog portal. According to CareFusion, the new
time-saving ordering system includes more than 12,000 different products that
are easily searched and sorted based on the product name or the type of
specialty in which they are used. CareFusion informed that the new system
includes pre-built and recommended trays for more than 25 common procedures
from nine different specialty areas including Cardiovascular, Ear Nose and
Throat, General and Micro Surgery, Laparoscopic Surgery, Neurology and Spine,
Obstetrics and Gynecology, Ophthalmic, Oral Surgery, and Orthopedic. The Full
Research Report on CareFusion Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/4933_CFN]

St. Jude Medical, Inc. Research Report

On August 29, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that
it has bagged the CE Mark approval for its EnligHTN Renal Denervation System
which is used to treat patients with drug-resistant uncontrolled hypertension.
According to the Company, the new system has an advanced generator that
delivers simultaneous ablations through a multi-electrode catheter, which
reduces total ablation time from c.24 minutes required by the first generation
system to four minutes by the new system. Frank J. Callaghan, President of the
St. Jude Medical Cardiovascular and Ablation Technologies Division, said, "The
next generation EnligHTN system offers physicians our proven multi-electrode
catheter with a new intuitive, faster generator that quickly and effectively
delivers consistent ablations with a significant reduction in procedure time.
These advancements deliver on our strategy to bring new innovations to a
developing market to provide options for patients who currently do not have an
adequate treatment for their uncontrolled drug-resistant hypertension." The
Full Research Report on St. Jude Medical, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ]

Community Health Systems Inc. Research Report

On August 22, 2013, Community Health Systems Inc. (CHS) and Cleveland Clinic
announced that they have been selected for exclusive negotiations in relation
to the purchase of certain assets of Akron General Health System. According to
the Company, the assets include Akron General Medical Center - a 532-bed acute
care hospital in Akron, Ohio; 70-bed Edwin Shaw Rehabilitation Hospital in
Cuyahoga Falls, Ohio; Lodi Community Hospital - a 25-bed critical access
hospital c.30 miles west of Akron, and other related healthcare facilities and
services. Community Health Systems stated that the parties will complete the
due diligence process and work toward finalizing the terms of a definitive
agreement. Wayne T. Smith, Chairman, President and CEO of CHS said, "The
strategic alliance formed between Cleveland Clinic and Community Health
Systems earlier this year is gaining momentum as we work together to advance
high-quality, cost-effective healthcare services within our own
organizations," The Full Research Report on Community Health Systems Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7587_CYH]

Neurocrine Biosciences, Inc. Research Report  

On August 29, 2013, Neurocrine Biosciences Inc. (Neurocrine Biosciences)
announced that in accordance to the Company's collaboration with AbbVie for
elagolix in 2010, the latter has initiated the second Phase III pivotal trial
to evaluate elagolix for the treatment of endometriosis. Neurocrine
Biosciences informed that the second Phase III trial is a 24-week,
multinational, randomized double-blind placebo-controlled study designed to
evaluate the safety and efficacy of elagolix in 788 women, age 18-49, with
moderate-to-severe endometriosis-associated pain. The Company expects to
provide top-line data from the second Phase III trial in Q3 2014 and complete
in 2015. The Full Research Report on Neurocrine Biosciences, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8228_NBIX]

Alnylam Pharmaceuticals Inc. Research Report

On August 28, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the
publication of complete study results from Phase I trials with ALN-TTR0a and
ALN-TTR02 in a article titled "Safety and Efficacy of RNAi Therapy for
Transthyretin Amyloidosis" in the New England Journal of Medicine. Alnylam
informed that the article shows that RNAi therapeutics targeting transthyretin
(TTR) achieved rapid, dose-dependent, durable, and specific knockdown of the
TTR, the disease causing protein in the TTR mediated amyloidosis (ATTR).
Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical
Officer of Alnylam, said, "The Phase I studies of ALN-TTR01 and ALN-TTR02
demonstrate key human proof of concept for RNAi therapeutics targeting TTR but
also for liver-expressed target genes in general, and we are thrilled to be
publishing these landmark data in the New England Journal of Medicine.
Notably, this is the first time that clinical results with an RNAi therapeutic
have been published in the Journal, and we are proud to be associated with
this milestone as we lead the clinical translation of RNAi therapeutics as a
whole new class of innovative medicines." The Full Research Report on Alnylam
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement